CO2025006994A2 - Anticuerpos anti–cd137 y métodos de uso - Google Patents
Anticuerpos anti–cd137 y métodos de usoInfo
- Publication number
- CO2025006994A2 CO2025006994A2 CONC2025/0006994A CO2025006994A CO2025006994A2 CO 2025006994 A2 CO2025006994 A2 CO 2025006994A2 CO 2025006994 A CO2025006994 A CO 2025006994A CO 2025006994 A2 CO2025006994 A2 CO 2025006994A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- antibody
- antigen
- methods
- specifically bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022133148 | 2022-11-21 | ||
| CN2022133147 | 2022-11-21 | ||
| CN2023126252 | 2023-10-24 | ||
| PCT/CN2023/132564 WO2024109678A1 (en) | 2022-11-21 | 2023-11-20 | Anti-cd137 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2025006994A2 true CO2025006994A2 (es) | 2025-06-06 |
Family
ID=91195249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2025/0006994A CO2025006994A2 (es) | 2022-11-21 | 2025-05-27 | Anticuerpos anti–cd137 y métodos de uso |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250154279A1 (https=) |
| EP (1) | EP4623005A1 (https=) |
| JP (1) | JP2025539145A (https=) |
| KR (1) | KR20250110345A (https=) |
| CN (2) | CN121378482A (https=) |
| AR (1) | AR131126A1 (https=) |
| AU (1) | AU2023384497A1 (https=) |
| CL (1) | CL2025001474A1 (https=) |
| CO (1) | CO2025006994A2 (https=) |
| IL (1) | IL320949A (https=) |
| MX (1) | MX2025005847A (https=) |
| TW (1) | TW202421665A (https=) |
| WO (1) | WO2024109678A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6845846B6 (ja) * | 2015-09-22 | 2021-04-21 | ディンフー バイオターゲット カンパニー リミテッド | 抗ヒトｃｄ１３７の完全ヒト抗体及びその用途 |
| AU2018224094B2 (en) * | 2017-02-24 | 2025-04-17 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| EP3615574A4 (en) * | 2017-04-26 | 2021-02-24 | Eureka Therapeutics, Inc. | SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE |
| AU2018301393B2 (en) * | 2017-07-11 | 2025-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| EP3710478A1 (en) * | 2017-11-13 | 2020-09-23 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
| CN110003332B (zh) * | 2018-01-05 | 2021-05-11 | 上海原能细胞医学技术有限公司 | Cd137抗体及其应用 |
| CN120098128A (zh) * | 2019-01-02 | 2025-06-06 | Qlsf生物治疗药物公司 | Cd137激动剂抗体及其用途 |
-
2023
- 2023-11-20 IL IL320949A patent/IL320949A/en unknown
- 2023-11-20 KR KR1020257020688A patent/KR20250110345A/ko active Pending
- 2023-11-20 CN CN202511287789.8A patent/CN121378482A/zh active Pending
- 2023-11-20 AU AU2023384497A patent/AU2023384497A1/en active Pending
- 2023-11-20 JP JP2025529229A patent/JP2025539145A/ja active Pending
- 2023-11-20 EP EP23893768.4A patent/EP4623005A1/en active Pending
- 2023-11-20 WO PCT/CN2023/132564 patent/WO2024109678A1/en not_active Ceased
- 2023-11-20 CN CN202380079710.5A patent/CN120225562A/zh active Pending
- 2023-11-21 TW TW112145023A patent/TW202421665A/zh unknown
- 2023-11-21 AR ARP230103131A patent/AR131126A1/es unknown
-
2024
- 2024-11-20 US US18/954,427 patent/US20250154279A1/en active Pending
-
2025
- 2025-05-19 CL CL2025001474A patent/CL2025001474A1/es unknown
- 2025-05-19 MX MX2025005847A patent/MX2025005847A/es unknown
- 2025-05-27 CO CONC2025/0006994A patent/CO2025006994A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250110345A (ko) | 2025-07-18 |
| MX2025005847A (es) | 2025-06-02 |
| CN120225562A (zh) | 2025-06-27 |
| JP2025539145A (ja) | 2025-12-03 |
| TW202421665A (zh) | 2024-06-01 |
| AR131126A1 (es) | 2025-02-19 |
| CN121378482A (zh) | 2026-01-23 |
| WO2024109678A1 (en) | 2024-05-30 |
| IL320949A (en) | 2025-07-01 |
| EP4623005A1 (en) | 2025-10-01 |
| CL2025001474A1 (es) | 2025-09-05 |
| AU2023384497A1 (en) | 2025-06-12 |
| US20250154279A1 (en) | 2025-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000934A1 (es) | Agente terapéutico que induce citotoxicidad (divisional de la solicitud no. 201700704) | |
| MX2025000370A (es) | Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos | |
| CL2023002108A1 (es) | Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso. | |
| CO2021016552A2 (es) | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso | |
| CO2022007924A2 (es) | Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| MX2016009554A (es) | Anticuerpos humanos para pd-1. | |
| CO2018004930A2 (es) | Moléculas de unión específicas para asct2 | |
| MX2023011121A (es) | Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos. | |
| CL2025001913A1 (es) | Anticuerpo anti-nectina-4; conjugado que lo comprende; composición farmacéutica; y su uso. | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| MX2025003354A (es) | Anticuerpos que se unen a 5t4 | |
| ECSP21044421A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| CO2021000386A2 (es) | Anticuerpos humanizados contra psma | |
| BR112016024214B8 (pt) | Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal | |
| CO2025002301A2 (es) | Anticuerpos anti-ccr8 y métodos de uso | |
| MX2022001065A (es) | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. | |
| CO2023017609A2 (es) | Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso | |
| CO2025008154A2 (es) | Conjugados anticuerpo–fármaco anti–cea y métodos de uso | |
| CL2022002404A1 (es) | Anticuerpos anti-gitr y usos de estos | |
| CO2025006994A2 (es) | Anticuerpos anti–cd137 y métodos de uso | |
| AR129382A1 (es) | Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso | |
| CO2025013101A2 (es) | Anticuerpos multiespecíficos anti–cd3 y métodos de uso | |
| CL2025002693A1 (es) | Anticuerpos multiespecíficos anti-cd3 y métodos de uso. | |
| CO2025013215A2 (es) | Anticuerpos multiespecíficos anti–cldn6 y anti–cd3 y métodos de uso |